Annovis Bio (US: ANVS) - Investment Thesis - Ayera Capital - Biotechnology Opportunity Deck
Annovis Bio is a development-stage biotechnology company addressing neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. Its lead drug candidate, ANVS401, finished its phase 2 trials for AD and PD.
It is one of the most undervalued and misunderstood biotech company on the market because of a misunderstanding of its clinical results. A strong body of fundamental research and human trial data interpreted with the context point to a convergence towards the same conclusion, which is the improvement of patients’ cognitive, motor and physiological functions.
Several catalysts are expected in 2022, notably the initiation of two phase 3 studies for AD and PD. Besides, management is ultra-committed (insiders own 32% of the stock), confident in their compound (they bought more shares in the open market in October 2021) and the float is super low. All these factors could send the share price to the moon in case of good news.
The full investment thesis is available here:
Who are we?
Ayera Capital is a multi-asset & multi-strategy investment platform specialised in technology.
Our aim is to demystify financial jargon and investment instruments with attractive returns and measured risk.
More about the author of the article: Hei-Hang Lui.
Discover our investment club as a visitor or as a member now.
Before any investment, please inform yourself about the risks. Ayera Capital Club cannot be held responsible, please read our legal notice.